We explore noninvasive clinical applications of multiple disease‐specific fusion markers
recently discovered in prostate cancer to predict the risk of cancer occurrence and …

BACKGROUND Current methods for detecting TMPRSS2-ERG fusion transcript in the urine
of patients with suspected prostate cancer lack diagnostic sensitivity. We combined urine …

Objectives The objective of this study was to combine urine and prostate biopsy rinse
material (BRM) assays to increase sensitivity for fusion gene detection. Patients and …

BACKGROUND: The TMPRSS2: ERG fusion is both prevalent and unique to prostate cancer
(PCa) and has great potential for noninvasive diagnosis of PCa in bodily fluids …

Background: TMPRSS2: ERG fusions are promising prostate cancer biomarkers. Because
they can occur in multiple forms in a single cancer specimen, we developed a quantitative …

Background Prostate cancer antigen 3 (PCA3) and v-ets erythroblastosis virus E26
oncogene homolog (TMPRSS2-ERG) gene fusions are promising prostate cancer (PCa) …

Prostate specific antigen (PSA) remains the most used biomarker in the management of
early prostate cancer (PCa), in spite of the problems related to false positive results and …

Purpose Localised prostate cancer diagnosis and management is increasingly complex due
to its heterogeneous progression and prognostic subgroups. Pitfalls in current screening …

BACKGROUND The prostate cancer gene 3 (PCA3) and TMPRSS2: ERG gene fusion are
promising prostate cancer (PCa) specific biomarkers. Our aim was to simultaneously …

Purpose: Early detection of prostate cancer can increase the curative success rate for
prostate cancer. We studied the diagnostic usefulness of TMPRSS2-ERG fusion transcripts …